Q1 2020 Abeona Therapeutics Inc Earnings Call

Abeona Therapeutics Inc. (ABEO), a fully-integrated leader in gene and cell therapy, today announced that researchers from the Abigail Wexner Research Institute (AWRI) at Nationwide Children’s Hospital presented positive interim data from two ongoing Phase I/II clinical trials evaluating ABO-102 and ABO-101, the Company’s investigational gene therapies for MPS IIIA and MPS IIIB, respectively, at WORLDSymposium™. Results from the Transpher A study demonstrated that MPS IIIA patients younger than 30 months treated with ABO-102 in dose cohort 3 continue to show neurocognitive development 18 months to two years after treatment.

Investors who purchased the Company's securities between May 31, 2018 and September 23, 2019, inclusive (the ''Class Period''), are encouraged to contact the firm before January 2, 2020. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.

Q1 2020 Abeona Therapeutics Inc Earnings Call

On track to treat first RDEB patient in pivotal Phase 3 VIITAL™ study of EB-101 in Q1 2020 Positive interim data from MPS IIIA and MPS IIIB programs presented at.

The art and science of stock market investing requires a tolerance for losing money on some of the shares you buy. But...

Abeona Therapeutics Inc. (ABEO), a fully-integrated leader in gene and cell therapy, today announced that the United States Patent and Trademark Office (USPTO) issued a patent covering next-generation adeno-associated virus (AAV) capsids generated using the University of North Carolina’s (UNC) AIM™ vector platform and that the USPTO allowed the claims of a companion patent application, which will issue in the next several weeks. Both patents are exclusively licensed by the Company from UNC. On January 14, 2020, the USPTO issued UNC’s U.S. Patent No. 10,532,110, entitled “AAV Vectors Targeted to the Central Nervous System.” The patent provides protection for methods of delivering Abeona’s AAV204-based gene therapy vectors to the central nervous system until November 2036.

NEW YORK, May 8, 2020 /PRNewswire/ -- Dashboard Camera Market Size, Share & Trends Analysis Report By Technology (Basic, Advanced, Smart), By Product, By Video Quality, By Application, By Distribution Channel, By Region, And Segment Forecasts, 2020 - 2027 Rea…

Investors who take an interest in Abeona Therapeutics Inc. (NASDAQ:ABEO) should definitely note that insider Stefano...

The COVID-19 pandemic has created extraordinary challenges across all aspects of healthcare. Above all, we will take every reasonable measure to ensure the safety of our patients and employees, while sustaining our business operations during this uncertain time. Abeona is fully focused on getting through the pandemic by working closely with our clinical trial sites to ensure that patient safety remains paramount.

Abeona Therapeutics Inc. (ABEO), a fully-integrated leader in gene and cell therapy, today announced that it has received Institutional Review Board (IRB) approval from Stanford University to commence the VIITAL™ study, the Company’s pivotal Phase 3 clinical trial evaluating EB-101 for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). The majority of patients targeted for enrollment have completed the pre-screening process at Stanford, and the Company expects the first patient in the VIITAL™ study to be treated in the first quarter of 2020. “We expect 2020 to be a transformational year at Abeona, and we are proud to start it with the initiation of our pivotal Phase 3 study evaluating EB-101 in RDEB,” said João Siffert, M.D., Chief Executive Officer.

Q4 2019 Abeona Therapeutics Inc Earnings Call

Abeona Therapeutics Inc. (ABEO), a fully-integrated leader in gene and cell therapy, today announced that investigators at Stanford University Medical Center have treated the first patient in the pivotal phase III VIITAL™ study evaluating EB-101, the Company’s gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa (RDEB). “Treating the first patient in our pivotal Phase III VIITAL™ study is an important achievement for the EB-101 program, now the most advanced gene therapy program in RDEB,” said João Siffert, M.D., Chief Executive Officer.

Pacira (PCRX) beats on both earnings and revenues in the first quarter of 2020. The company temporarily suspends 2020 guidance in the wake of the COVID-19 pandemic.

Investors who purchased the Company's securities between May 31, 2018 and September 23, 2019, inclusive (the ''Class Period''), are encouraged to contact the firm before January 2, 2020. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.

Dashboard Camera Market Size, Share & Trends Analysis Report By Technology (Basic, Advanced, Smart), By Product, By Video Quality, By Application, By Distribution Channel, By Region, And Segment Forecasts, 2020 - 2027Read the full report: https://www.reportli…

NEW YORK and CLEVELAND, Jan. 21, 2020 -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced its participation in the.

NEW YORK, April 17, 2020 -- Fields Kupka & Shukurov LLP is investigating potential breach of fiduciary duty claims involving the board of directors of Abeona Therapeutics.

NEW YORK, NY / ACCESSWIRE / January 2, 2020 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Abeona Therapeutics Inc. ("Abeona" or "the ...

NEW YORK and CLEVELAND, April 21, 2020 -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced appointments of Brian.

Abeona Therapeutics Inc. (ABEO), a fully-integrated leader in gene and cell therapy, today announced it granted options to Brian Pereira, M.D., the newly-appointed Executive Chairman of the Company, to purchase 930,000 shares of Abeona common stock. The stock options have a $2.50 exercise price per share, which is equal to the closing price of Abeona's common stock on the grant date. The options were offered as a material inducement to Dr. Pereira’s appointment as Executive Chairman.

The smid-cap biotech earnings deluge hit Wall Street in the week ended May 9, positively impacting the stocks in the sector. The iShares NASDAQ Biotechnology Index (NASDAQ: IBB) gained about 6% for the week.Large-cap pharma names AstraZeneca plc (NYSE: AZN) a…

The FDA issues a CRL to Blueprint Medicines' (BPMC) NDA for Ayvakit to treat adults with unresectable/metastatic fourth-line GST.

Abeona Therapeutics Inc. (ABEO), a fully-integrated leader in gene and cell therapy, today announced first quarter 2020 financial results, which will be discussed on a conference call scheduled for Thursday, May 7, 2020 at 8:30 a.m. ET. “During these challenging times, our priority remains to ensure the safety of our employees and patients, while supporting continuity of our business and clinical operations,” said João Siffert, M.D., Chief Executive Officer of Abeona. It is our intention to restore full patient access to our clinical programs as soon as possible.

NEW YORK and CLEVELAND, Feb. 26, 2020 -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that João Siffert, M.D.,.

Insights into the Worldwide Dashboard Camera Industry to 2027 - by Technology, Product, Video Quality, Application, Distribution Channel, Region and Segment Forecasts  GlobeNewswire